The report "European NGS Services Market by Technology (SBS, SBL, SMRT, Pyrosequencing), Application (Exome Sequencing, CHIP-Seq), End User (Pharmaceutical Companies, Hospital), Disease [Oncology (Prostate, Lung, & Breast Cancer), Rare Diseases) - Forecast to 2020", analyzes and studies the major market drivers, restraints, opportunities, and challenges in Europe.
Browse 67 market data tables and 12 figures spread through 222 pages and in-depth TOC on “European NGS Services Market by Technology (SBS, SBL, SMRT, Pyrosequencing), Application (Exome Sequencing, CHIP-Seq), End User (Pharmaceutical Companies, Hospital), Disease (Oncology (Prostate, Lung, & Breast Cancer), Rare Diseases) - Forecast to 2020"
Early buyers will receive 10% customization on reports.
The NGS services market in Europe is expected to reach USD 1,152 Million by 2020 from USD 444 Million in 2015, at a CAGR of 21% from 2015 to 2020.
The report segments the European NGS services market on the basis of technology, application, end user, disease type, and country. Major applications of NGS services include whole-genome sequencing, exome sequencing, targeted sequencing/gene panels,
De novo sequencing, RNA-seq, ChiP-seq, and methyl-seq. The exome sequencing application segment is forecasted to be the fastest-growing segment during the forecast period. The exome and untranslated regulatory regions (UTRs) comprise only 1% to 2% of the human genome, yet contain as many as 85% of disease-related mutations and thus exome sequencing is considered as one of the important tools in NGS. Also, exome sequencing requires less time and resources and enables producing results at a low cost and greater speed and resolution.
Regionally, the market is segmented into the U.K., Germany, France, Italy, Spain, Netherlands, and Rest of the Europe (RoE). The U.K. is estimated to account for the largest share of the European NGS services market in 2015 and is also poised to be the fastest-growing region during the forecast period.
Key players in the European NGS services market include the Beijing Genomics Institute (BGI) (China), Macrogen (South Korea), Eurofins Genomics (Germany), Illumina (U.S.), DNA Vision (Belgium), CeGaT GmbH (Germany), Febit (U.S.), Genomnia (Italy), Microsynth (Switzerland), and Source Bioscience (U.K.).
MarketsandMarkets is world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
Markets and Markets
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India
Email: [email protected]